^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DLL3-targeted antibody-drug conjugate

    Related drugs:
    4d
    ZL-1310-001: A Study of ZL-1310 in Subjects With Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=339, Recruiting, Zai Lab (Shanghai) Co., Ltd. | N=112 --> 339
    Enrollment change
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Tecentriq (atezolizumab) • carboplatin
    1m
    A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    New P1 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    IDH wild-type
    1m
    A Study of FZ-AD005 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=162, Recruiting, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Trial completion date: Jun 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial completion date • Trial primary completion date • First-in-human
    2ms
    A Study of ZL-1310 in Participants With Selected Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Zai Lab (Shanghai) Co., Ltd. | N=86 --> 112 | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Aug 2027
    Enrollment change • Trial completion date • Trial primary completion date
    3ms
    ZL-1310-003: A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=480, Recruiting, Zai Lab (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> Nov 2028 | Trial primary completion date: Nov 2028 --> Jun 2028
    Enrollment open • Trial completion date • Trial primary completion date
    4ms
    A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=208, Recruiting, IDEAYA Biosciences | N=90 --> 208
    Enrollment change
    |
    Imfinzi (durvalumab) • IDE161
    4ms
    A novel nomogram based on DLL3 and PD-L1 for predicting the prognosis of patients with small cell lung cancer. (PubMed, BMC Cancer)
    The prognostic model developed in this study offers predictive value in estimating 12-month survival probability for SCLC patients, aiding clinicians in making more informed treatment decisions.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    PD-L1 expression • KIT expression
    |
    Rova-T (rovalpituzumab tesirine)
    6ms
    A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=665, Not yet recruiting, Zai Lab (Shanghai) Co., Ltd.
    New P3 trial
    6ms
    Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=120, Recruiting, SystImmune Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Apr 2025
    Enrollment open • Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    6ms
    Antibody Drugs Conjugates in Small-Cell Lung Cancer: Present-Day Status and Promises. (PubMed, Oncologist)
    While ADCs have generated encouraging response rates in SCLC, durability has remained limited. Future development will require optimization of payloads, linkers, and trial design to determine whether ADCs can achieve a sustained role in this disease.
    Journal
    |
    CD276 (CD276 Molecule) • DLL3 (Delta Like Canonical Notch Ligand 3) • SEZ6 (Seizure Related 6 Homolog)
    7ms
    A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=90, Recruiting, IDEAYA Biosciences
    New P1/2 trial
    8ms
    A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=120, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)